Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $68.52 USD
Change Today +1.02 / 1.51%
Volume 1.8M
As of 11:25 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/20/15 - $69.86
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

uniQure N.V. Announces Closing of Strategic Collaboration with Bristol-Myers Squibb to Develop Gene Therapies for Cardiovascular Disease

uniQure N.V. announced the closing of its strategic collaboration with Bristol-Myers Squibb to develop gene therapies for cardiovascular disease. The transaction was previously announced on April 6, 2015. This collaboration brings together the company’s innovative and validated gene therapy platform and Bristol-Myers Squibb's expertise in discovering and developing treatments for cardiovascular diseases in an effort to advance the promise of gene therapy for the millions of patients that suffer from heart disease. The partnership enables the company’s to significantly accelerate and expand its cardiovascular product pipeline and complements the further development of its internal product candidates targeting liver diseases, such as hemophilia, and CNS disorders, including lysosomal storage diseases. The collaboration agreement provides Bristol-Myers Squibb with exclusive access to uniQure's gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQure's proprietary gene therapy program for congestive heart failure that is intended to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. Beyond cardiovascular diseases, the agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on ten targets, including S100A1. Under the terms of the agreement, Bristol-Myers Squibb will make near-term payments of approximately $100 million, including an initial upfront payment of $50 million upon closing of the transaction, a $15 million payment upon selection of three collaboration targets, in addition to S100A1, to be made within three months of closing, and an initial equity investment in uniQure representing 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or approximately $37 million in total. The initial equity investment is expected to close on June 12, 2015. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration. uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254 million for the lead S1A001 therapeutic and up to $217 million for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales based milestone payments and tiered single to double-digit royalties on product sales.

Bristol-Myers Squibb Company Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients. The updated Designation reflects recently presented data on HCV genotype 1 patients with advanced cirrhosis (Child-Pugh Class B or C) and those who develop genotype 1 HCV recurrence post-liver transplant. Breakthrough Therapy Designation requires preliminary clinical evidence that demonstrates a drug may have substantial improvement on at least one clinically significant endpoint over available therapy. The designation is supported by data from ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with HCV with either advanced cirrhosis or post-liver transplant recurrence of HCV. Results from ALLY-1 were recently presented at The International Liver Congress 2015, this year’s annual meeting of the European Association for the Study of the Liver. According to the FDA, Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The FDA first granted a Designation for the daclatasvir and sofosbuvir combination in 2013; since that time, there have been significant developments in the field of HCV. That has led the FDA to review, modify, and in some cases, rescind previously granted HCV-related Designations.

Bristol-Myers Squibb Company Announces the Pricing Terms of its Cash Tender Offer for Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities

Bristol-Myers Squibb Company announced the pricing terms of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of its outstanding debt securities. The total consideration for each series of notes includes an early tender premium of $30 per $1,000 principal amount of notes validly tendered and not validly withdrawn by such holders and accepted for purchase by Bristol-Myers Squibb. All payments for notes purchased in connection with the early tender date will also include accrued and unpaid interest on the principal amount of notes tendered up to, but not including, the initial settlement date, which is currently expected to be May 13, 2015. Bristol-Myers Squibb expects it will accept for purchase notes validly tendered and not validly withdrawn prior to the early tender date in an aggregate principal amount up to the tender cap. Tendered notes are expected to be accepted in the order of the acceptance priority levels. Bristol-Myers Squibb has previously announced the anticipated principal amount it expects to accept of each series of notes. The tender offer is scheduled to expire on May 26, 2015, unless extended or earlier terminated.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $68.51 USD +1.01

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.55 USD +1.45
Actavis plc $304.84 USD +4.77
Amgen Inc $160.55 USD +1.54
Medtronic PLC $76.93 USD +0.36
Novo Nordisk A/S kr394.10 DKK +4.00

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 50.7x
Price/Sales 7.1x
Price/Book 7.3x
Price/Cash Flow 50.5x
TEV/Sales 6.1x

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers' Opdivo Gets Positive Opinion from CHMP - Analyst Blog
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab
[at noodls] - Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinionfrom the CHMP in advanced non-small cell lung cancer Opinion based on overall survival benefit demonstrated in CheckMate ...
Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
[at noodls] - Breakthrough Designation for daclatasvir and sofosbuvir combination is supported by the recently presented ALLY-1 trial in patients with advanced cirrhosis or recurrent hepatitis C (HCV) after liver transplant ...
Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer and Increase Awareness of Innovative Immuno-Oncology Research
[at noodls] - Ready. Raise. Rise. encourages everyone touched by cancer to create a personalized, virtual flag in honor of a loved one and help raise money for cancer advocacy organizations New survey shows lack of ...
Bristol-Myers-AbbVie Drug Improves Remission in Blood Cancer
Coverage initiated on Bristol-Myers by Berenberg
Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology
[at noodls] - Pivotal Phase III studies (CheckMate -057 & -017) in both advanced non-squamous and squamous non-small cell lung cancer in which treatment with Opdivo demonstrated superior survival versus chemotherapy ...
Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities
[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain ...